| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. | Director | Common Stock | 70,000 | $48,202 | $0.6886 | 17 Jun 2025 | Direct |
| MANNKIND CORP | Director | Restricted Stock Unit | 52,854 | 14 May 2025 | Direct | ||
| MANNKIND CORP | Director | Restricted Stock Unit | 35,047 | 15 May 2024 | Direct | ||
| Xilio Therapeutics, Inc. | Director | Stock Option (right to buy) | 31,000 | 11 Jun 2025 | Direct | ||
| Horizon Therapeutics Public Ltd Co | Director | Ordinary Shares | 0 | $116.50 | 06 Oct 2023 | By Trust | |
| Horizon Therapeutics Public Ltd Co | Director | Ordinary Shares | 0 | $116.50 | 06 Oct 2023 | Direct | |
| Horizon Therapeutics Public Ltd Co | Director | Restricted Stock Units | 0 | 06 Oct 2023 | Direct | ||
| Horizon Therapeutics Public Ltd Co | Director | Stock Option (Right to Buy) | 0 | 06 Oct 2023 | Direct |